No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 165 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Virchow: The Largest Foundation Model for Computational Pathology To Date August 13, 2024 Sex, intimacy and cancer – That Cancer Conversation April 28, 2023 On legacy giving: “It allows me to give something more meaningful... October 13, 2021 EMA Recommends Extension of Therapeutic Indications for Olaparib June 27, 2022 Load more HOT NEWS When Prenatal DNA Tests Point to Cancer “My First Thought Was My Children:” Young Mom Diagnosed With Triple-Negative... Woman’s Doctors Kept Telling Her She Was ‘Just Overweight,’ Ended Up... Experimental Medulloblastoma Treatment Gets a Boost with Nanoparticles
